Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Popular Sleep Supplement Could Come With an Unexpected Catch, Scientists Warn (opens in a new tab)

scitechdaily.com · 2026-10-24

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 3 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two claims go beyond the study. One overstates it and one isn't supported at all. One claim the study doesn't address.

  • 3 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not supportedMice given CBN twice daily for three days developed tolerance and displayed withdrawal signs when it was removed, including head twitches and paw fluttering.View evidenceHide evidence

As statedtwice daily for three days

Why this verdict

The broad tolerance/withdrawal theme is present, but the claim is not accurate as stated. The abstract reports twice-daily CBN for five days, not three days, and withdrawal signs were precipitated by rimonabant on day 6 rather than simply appearing 'when it was removed.' The profile also reports paw tremors, not specifically 'paw fluttering.'

1

Study evidence

Repeated CBN administration produced tolerance to CBN-induced catalepsy in adult C57BL/6 mice.

“Adult C57BL/6 mice were administered CBN twice daily for five days and tested in the tetrad battery to measure tolerance.”
2

Study evidence

Rimonabant precipitated somatic withdrawal signs (head twitches, paw tremors) in mice that had received repeated CBN.

“On the sixth day, rimonabant was administered and somatic signs of withdrawal (i.e., head twitches and paw tremors) and struggling in the tail suspension test were assessed.”
Claim 2 of 6OverstatedA cannabis compound sold to help people sleep caused withdrawal symptoms in mice after just three days of repeated use.View evidenceHide evidence

As statedafter just three days of repeated use

Why this verdict

The abstract supports antagonist-precipitated withdrawal signs in CBN-treated mice, but not the headline's 'after just three days' framing. The paper profile describes CBN twice daily for five days, with rimonabant challenge on day 6. The headline therefore outruns the paper evidence on timing and simplifies the precipitated-withdrawal design.

1

Study evidence

Rimonabant precipitated somatic withdrawal signs (head twitches, paw tremors) in mice that had received repeated CBN.

“On the sixth day, rimonabant was administered and somatic signs of withdrawal (i.e., head twitches and paw tremors) and struggling in the tail suspension test were assessed.”
Claim 3 of 6Not coveredThe researchers also observed anti-inflammatory effects at lower CBN doses, but during a simulated bacterial challenge CBN dampened the immune response.View evidenceHide evidence

As statedlower doses

Why this verdict

The supplied abstract-level paper profile contains behavioral pharmacology findings on tolerance, withdrawal, cross-tolerance, and THC-like discriminative stimulus effects. It does not include anti-inflammatory or simulated bacterial-challenge immune-response findings, so this claim cannot be verified from the supplied abstract-depth evidence.

Claim 4 of 6SupportedResearchers at the University of Connecticut found that repeated doses of cannabinol, or CBN, produced tolerance and withdrawal symptoms in mice.View evidenceHide evidence

As statedrepeated doses

Why this verdict

The abstract supports that repeated CBN dosing in mice produced tolerance to several cannabimimetic outcomes and that rimonabant precipitated somatic withdrawal signs in CBN-treated mice.

1

Study evidence

Repeated CBN administration produced tolerance to CBN-induced catalepsy in adult C57BL/6 mice.

“Adult C57BL/6 mice were administered CBN twice daily for five days and tested in the tetrad battery to measure tolerance.”
2

Study evidence

Rimonabant precipitated somatic withdrawal signs (head twitches, paw tremors) in mice that had received repeated CBN.

“On the sixth day, rimonabant was administered and somatic signs of withdrawal (i.e., head twitches and paw tremors) and struggling in the tail suspension test were assessed.”
Claim 5 of 6SupportedA separate experiment suggested mice trained to respond to THC responded similarly to CBN, implying comparable internal cues.View evidenceHide evidence

Why this verdict

The abstract states that a separate cohort of mice was trained to discriminate THC from vehicle and that CBN fully substituted for THC, supporting the story's statement that CBN produced THC-like internal/discriminative cues in that paradigm.

1

Study evidence

CBN fully substituted for THC in mice trained to discriminate THC from vehicle.

“A separate cohort of mice was trained to discriminate THC from vehicle.”
Claim 6 of 6SupportedThe article stresses that the study involved mice, so there is substantial uncertainty about CBN’s effects in people, especially with prolonged use.View evidenceHide evidence

Why this verdict

The profile consistently describes in vivo mouse experiments, and the abstract-level limitations note limited generalizability details. The story's caveat that human implications remain uncertain is an appropriate limitation for mouse-only evidence.

1

Study evidence

Repeated CBN administration produced tolerance to CBN-induced catalepsy in adult C57BL/6 mice.

“Adult C57BL/6 mice were administered CBN twice daily for five days and tested in the tetrad battery to measure tolerance.”
2

Study evidence

Rimonabant precipitated somatic withdrawal signs (head twitches, paw tremors) in mice that had received repeated CBN.

“On the sixth day, rimonabant was administered and somatic signs of withdrawal (i.e., head twitches and paw tremors) and struggling in the tail suspension test were assessed.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Withdrawal evidence came from a rimonabant-precipitated withdrawal design on day 6 after repeated CBN exposure, with head twitches, paw tremors, and increased struggling in the tail suspension test.

    The story covers withdrawal signs, but it does not accurately reflect the antagonist-precipitated design and instead frames the signs as occurring after three days or when CBN was removed. That distinction is important for interpreting physical dependence evidence.

    From Antagonist-precipitated withdrawal after repeated CBN in mice

  • Repeated CBN exposure attenuated the cannabimimetic effects of WIN 55,212-2, indicating cross-tolerance.

    The story presentation does not mention the WIN 55,212-2 cross-tolerance experiment.

    From Cross-tolerance challenge

  • The drug-discrimination unit also reported that rimonabant was less effective at reducing CBN's discriminative effects than THC's at the tested dose, and that CBN plus THC attenuated THC's discriminative stimulus.

    The story mentions the CBN-for-THC substitution result but not these additional interaction findings from the same unit.

    From drug-discrimination (operant) in mice

3 things the story did carry across
  • Repeated CBN administration in adult C57BL/6 mice was twice daily for five days and produced tolerance to CBN-induced catalepsy, antinociception, and hypothermia.
  • In THC-trained mice, CBN fully substituted for THC in a drug-discrimination paradigm.
  • The evidence is limited to mouse models, with no direct evidence here on effects in humans.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDetermine whether repeated cannabinol (CBN) administration produces tolerance to classic cannabimimetic (tetrad) outcomes in mice.Repeated CBN dosing with tetrad assessmentExpand

In plain English

In adult C57BL/6 mice, repeated cannabinol (CBN) administration (twice daily for five days) produced tolerance to multiple cannabimimetic tetrad outcomes: catalepsy, antinociception, and hypothermia, as assessed in a tetrad battery.

Key findings

  • Repeated CBN administration produced tolerance to CBN-induced catalepsy in adult C57BL/6 mice.
  • Repeated CBN administration produced tolerance to CBN-induced antinociception in adult C57BL/6 mice.
“Adult C57BL/6 mice were administered CBN twice daily for five days and tested in the tetrad battery to measure tolerance.”
What this piece can’t prove
  • Abstract does not report CBN dose(s), route of administration, exact timing of dosing relative to testing, or sample sizes.

3 further details could not be confirmed from the summary.

2in vivo animalDetermine whether repeated CBN produces CB1-mediated physical dependence/withdrawal revealed by rimonabant challenge (somatic signs; tail suspension struggling).Antagonist-precipitated withdrawal after repeated CBN in miceExpand

In plain English

Adult C57BL/6 mice given cannabinol (CBN) twice daily for five days were administered the CB1 antagonist rimonabant on day 6; rimonabant precipitated measurable somatic withdrawal signs (head twitches, paw tremors) and increased struggling in the tail suspension test in CBN-treated mice, consistent with antagonist-precipitated withdrawal after repeated CBN exposure.

Key findings

  • Rimonabant precipitated somatic withdrawal signs (head twitches, paw tremors) in mice that had received repeated CBN.
  • Rimonabant increased struggling in the tail suspension test in CBN-treated mice.
“On the sixth day, rimonabant was administered and somatic signs of withdrawal (i.e., head twitches and paw tremors) and struggling in the tail suspension test were assessed.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vivo animalDetermine whether repeated CBN produces cross-tolerance to another cannabinoid receptor agonist (WIN 55,212-2) in mice.Cross-tolerance challengeExpand

In plain English

In adult C57BL/6 mice repeatedly administered cannabinol (CBN) twice daily for five days, subsequent challenge with the CB1/CB2 agonist WIN 55,212-2 produced attenuated cannabimimetic effects relative to controls, consistent with cross-tolerance between CBN and WIN 55,212-2.

Key findings

  • Cannabimimetic effects of WIN 55,212-2 were attenuated in CBN-treated mice, indicating cross-tolerance.
“Cross-tolerance to the CB1/CB2 agonist WIN 55,212-2 was also assessed in mice repeatedly administered CBN.”
What this piece can’t prove
  • Summary is based on abstract text only; full methods, doses, sample sizes, and statistical analyses are not available here.
  • Abstract does not report quantitative effect sizes, confidence intervals, or p-values for the WIN attenuation.

2 further details could not be confirmed from the summary.

4in vivo animalCharacterize the Δ9-THC-like interoceptive (drug-discriminative stimulus) effects of CBN in THC-trained mice, including interaction tests (rimonabant effects; CBN+THC co-administration effects on THC cue).drug-discrimination (operant) in miceExpand

In plain English

In mice trained to discriminate Δ9-THC from vehicle, cannabinol (CBN) fully substituted for the THC cue; a tested dose of rimonabant substantially attenuated THC's discriminative stimulus but was less effective at reducing CBN's discriminative effects; co-administration of CBN with THC attenuated THC's discriminative stimulus.

Key findings

  • CBN fully substituted for THC in mice trained to discriminate THC from vehicle.
  • Rimonabant substantially attenuated THC's discriminative/psychoactive effects at the tested dose, but the same dose was less effective in reducing CBN's discriminative effects.
“A separate cohort of mice was trained to discriminate THC from vehicle.”
What this piece can’t prove
  • Rimonabant effects reported for a single tested dose; dose–response relationships unknown.
  • Findings are limited to mice trained to discriminate THC from vehicle; generalizability to other species or to humans not addressed in abstract.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 29 candidate papers

And 23 more candidates considered.